

Thermo Fisher Scientific invests \$6 M to expand Viral Vector Manufacturing Facility

22 November 2019 | News

Investment doubles the site's process development capabilities and establishes commercial testing



Thermo Fisher Scientific, the world leader in serving science, on 22nd Nov 2019, unveiled the \$6 million expansion of its gene therapy and viral vector services site in Alachua, Florida. The investment doubles the site's laboratory and warehousing capacity for upstream process development and quality control testing of gene therapy products.

The expansion at the Alachua facility is part of Thermo Fisher's \$270 million investment this year to expand its capabilities, capacity and talent globally to enable its customers to develop and deliver high-quality medicines to patients around the world. This investment follows the company's recent acquisition of Brammer Bio, a leader in viral vector manufacturing.

"The team at our Alachua site has more than 12 years of expertise developing processes, analytics and manufacturing GMP materials to help our customers with the clinical development of advanced medicines for rare and complex diseases," said Chris Murphy, vice president and general manager, viral vector services at Thermo Fisher. "This investment in Alachua signifies our continued commitment to serve our gene therapy customers and their patients in need."

"Thermo Fisher's investment to expand here in Alachua highlights our reputation as a destination for the biotech industry," said Eric Godet, CEO of the Greater Gainesville Chamber of Commerce. "As the company continues to grow to serve its customers around the globe with medical advancements, so do the economic and workforce opportunities for our community."